TY - STD TI - Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy [Internet]. 2014 [cited 2016 Apr 8];69(7):e1–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24898678. UR - http://www.ncbi.nlm.nih.gov/pubmed/24898678 ID - ref1 ER - TY - STD TI - Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy [Internet]. 2011 [cited 2016 Mar 29];66(3):317–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21083565. UR - http://www.ncbi.nlm.nih.gov/pubmed/21083565 ID - ref2 ER - TY - STD TI - Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol [Internet]. 2008 [cited 2016 Mar 1];144(1):35–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18209166. UR - http://www.ncbi.nlm.nih.gov/pubmed/18209166 ID - ref3 ER - TY - STD TI - Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol [Internet]. 1994 [cited 2016 Mar 1];19(3):210–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8033378. UR - http://www.ncbi.nlm.nih.gov/pubmed/8033378 ID - ref4 ER - TY - STD TI - Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med [Internet]. Massachusetts Medical Society; 2013 [cited 2016 Apr 8];368(10):924–35. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1215372 UR - http://www.nejm.org/doi/full/10.1056/NEJMoa1215372 ID - ref5 ER - TY - STD TI - Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol [Internet]. 2015 [cited 2016 Apr 5];135(1):67–75. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4269803&tool=pmcentrez&rendertype=abstract. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4269803&tool=pmcentrez&rendertype=abstract ID - ref6 ER - TY - JOUR AU - Kaplan, A. AU - Ledford, D. AU - Ashby, M. AU - Canvin, J. AU - Zazzali, J. L. AU - Conner, E. PY - 2013 DA - 2013// TI - Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy JO - J Allergy Clin Immunol VL - 132 UR - https://doi.org/10.1016/j.jaci.2013.05.013 DO - 10.1016/j.jaci.2013.05.013 ID - Kaplan2013 ER - TY - STD TI - Labrador-Horrillo M, Valero A, Velasco M, Jáuregui I, Sastre J, Bartra J, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther [Internet]. 2013 [cited 2016 Apr 8];13(9):1225–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23875845. UR - http://www.ncbi.nlm.nih.gov/pubmed/23875845 ID - ref8 ER - TY - STD TI - Sussman G, Hébert J, Barron C, Bian J, Caron-Guay R-M, Laflamme S, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol [Internet]. 2014 [cited 2016 Apr 8];112(2):170–4. Available from: http://www.sciencedirect.com/science/article/pii/S1081120613009265. UR - http://www.sciencedirect.com/science/article/pii/S1081120613009265 ID - ref9 ER - TY - JOUR AU - Romano, C. AU - Sellitto, A. AU - Fanis, U. AU - Esposito, G. AU - Arbo, P. AU - Giunta, R. PY - 2010 DA - 2010// TI - Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria JO - Ann Allergy Asthma Immunol VL - 104 UR - https://doi.org/10.1016/j.anai.2009.11.017 DO - 10.1016/j.anai.2009.11.017 ID - Romano2010 ER - TY - JOUR AU - Maurer, M. AU - Altrichter, S. AU - Bieber, T. AU - Biedermann, T. AU - Bräutigam, M. AU - Seyfried, S. PY - 2011 DA - 2011// TI - Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase JO - J Allergy Clin Immunol VL - 128 UR - https://doi.org/10.1016/j.jaci.2011.04.038 DO - 10.1016/j.jaci.2011.04.038 ID - Maurer2011 ER - TY - STD TI - Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol [Internet]. 2011;128(3):567–73. e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21762974. UR - http://www.ncbi.nlm.nih.gov/pubmed/21762974 ID - ref12 ER - TY - STD TI - Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy [Internet]. 2008 [cited 2016 Apr 8];63(6):777–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18445192. UR - http://www.ncbi.nlm.nih.gov/pubmed/18445192 ID - ref13 ER - TY - STD TI - Ensina LF, Valle SOR, Juliani AP, Galeane M, Vieira Dos Santos R, Arruda LK, et al. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience. Int Arch Allergy Immunol [Internet]. 2016 [cited 2016 Apr 8];169(2):121–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27055122. UR - http://www.ncbi.nlm.nih.gov/pubmed/27055122 ID - ref14 ER - TY - JOUR AU - Rottem, M. AU - Segal, R. AU - Kivity, S. AU - Shamshines, L. AU - Graif, Y. AU - Shalit, M. PY - 2014 DA - 2014// TI - Omalizumab therapy for chronic spontaneous urticaria: The Israeli experience JO - Isr Med Assoc J VL - 16 ID - Rottem2014 ER - TY - JOUR AU - Kaplan, A. AU - Ferrer, M. AU - Bernstein, J. A. AU - Antonova, E. AU - Trzaskoma, B. AU - Raimundo, K. PY - 2016 DA - 2016// TI - Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria JO - J Allergy Clin Immunol VL - 137 UR - https://doi.org/10.1016/j.jaci.2015.08.023 DO - 10.1016/j.jaci.2015.08.023 ID - Kaplan2016 ER - TY - JOUR AU - Uysal, P. AU - Eller, E. AU - Mortz, C. G. AU - Bindslev-Jensen, C. PY - 2014 DA - 2014// TI - An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized JO - J Allergy Clin Immunol VL - 133 UR - https://doi.org/10.1016/j.jaci.2013.10.015 DO - 10.1016/j.jaci.2013.10.015 ID - Uysal2014 ER - TY - STD TI - Palacios T, Stillman L, Borish L, Lawrence M. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract [Internet]. American Academy of Allergy, Asthma & Immunology; 2015;1–2. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26725153. UR - https://www.ncbi.nlm.nih.gov/pubmed/26725153 ID - ref18 ER -